Q-Med AB Sustainability Profile
Q-Med AB, a pioneering company in the medical technology sector, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 1988, Q-Med has established itself as a leader in the development of innovative hyaluronic acid-based products, particularly in the fields of aesthetics and regenerative medicine. The company’s flagship offerings include the renowned Restylane® range, which revolutionised facial aesthetics, and other advanced medical devices that enhance patient care. Q-Med's commitment to quality and scientific research has positioned it as a trusted name in the industry, with numerous accolades highlighting its contributions to healthcare. With a focus on improving patient outcomes, Q-Med continues to drive advancements in medical technology, solidifying its reputation as a key player in the global market.
DitchCarbon Score
How does Q-Med AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Q-Med AB's score of 37 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Q-Med AB, headquartered in Sweden (SE), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Galderma Group AG, which may influence its climate commitments and reporting practices. As of now, Q-Med AB has not established any documented reduction targets or climate pledges. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of its parent company, Galderma Group AG, it is possible that Q-Med AB's climate commitments could align with broader initiatives undertaken by the group, although specific details are not available at this time. In summary, Q-Med AB's current climate commitments and emissions data remain unspecified, reflecting a potential area for future development in sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 9,800,000 | 0,000,000 |
| Scope 2 | 4,200,000 | 000,000 |
| Scope 3 | - | 000,000,000 |
How Carbon Intensive is Q-Med AB's Industry?
How Carbon Intensive is Q-Med AB's Location?
Q-Med AB's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Q-Med AB has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
